Zhen Yongzhan, Shang Boyang, Liu Xiujun, Lin Yajun, Zhen Yongsu
Department of Histology and Embryology, Basic Medical College, Hebei United University, Hebei, Beijing, China.
J Cancer Res Ther. 2016 Jan-Mar;12(1):182-7. doi: 10.4103/0973-1482.146093.
The aim of this study is to explore the antitumor efficacy of lidamycin (LDM) against human multiple myelomas (MM).
Human MM RPMI 8226 cells and the xenograft model in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were used to examine the antitumor activity of LDM.
Notably, LDM markedly suppressed the growth of human MM RPMI 8226 xenograft in NOD/SCID mice. In vitro, there was a significant reduction in cell proliferation after treatment with LDM. The overall growth inhibition correlated with the increase of apoptotic cells. The apoptosis-related proteins including caspase-3, 7, and 9 were activated, and poly adenosine diphosphate-ribose polymerase was cleaved. Further investigation revealed that cellular Bcl-2 and survivin decreased, whereas the level of Bax increased in the LDM-treated cells.
LDM is highly effective against the growth of MM xenograft in NOD/SCID mice. The potent apoptosis.inducing effect of LDM may be mediated through caspase. and mitochondria.dependent pathway.
